Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ABVX News 20 November 2025 - 7 January 2026

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

NEW YORK — Friday, December 26, 2025 (9:13 a.m. ET): U.S. stocks are heading into a thin, post‑Christmas trading day, with Wall Street set for a relatively muted open as investors digest a strong 2025 tape and look ahead to 2026 rate and earnings narratives. Reuters In that kind of tape, headline-driven biotech names can swing harder than usual—and ABIVAX Société Anonyme (NASDAQ: ABVX) has been exactly that kind of stock in December: a mix of clinical-trial enthusiasm, index-related positioning, and renewed takeover speculation. As of the latest available quote this morning, ABVX was trading around $145.31 in the premarket,
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme (ticker ABVX on Nasdaq and Euronext Paris) is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index (NBI), effective before today’s market open. GlobeNewswire+2Investing.com+2 In early market action, multiple outlets reported double‑digit gains in Abivax’s U.S. premarket trading and strong moves in Paris, making ABVX one of the morning’s most-watched biotech tickers. Benzinga+2Investing.com+2 But the bigger reason ABIVAX stock keeps showing up in “top movers” lists isn’t just rumor-driven volatility. The
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

December 16, 2025 — ABIVAX Société Anonyme (listed as ABVX on Euronext Paris and Nasdaq) is back in the spotlight today after publishing third-quarter 2025 financial results and reiterating a long cash runway—news that didn’t stop the stock from pulling back as investors digested widening losses and the sheer scale of the rally already priced in. In U.S. trading, Abivax’s Nasdaq-listed shares were down about 5% around mid-session, at roughly $111–$112. StockAnalysis In Paris, Abivax shares were also lower earlier in the day, with one market report citing a drop of about 5.7% during the European morning. Investing.com South Africa
16 December 2025
···
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme (Euronext Paris: ABVX, Nasdaq: ABVX) is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease (IBD) contender.Reuters+1 Below is a detailed rundown of today’s news, the fundamental drivers, and the latest forecasts and analyses being published about Abivax. 1. Abivax stock today: how big is the move? On December 10, 2025, Abivax shares on Euronext Paris traded around
10 December 2025
····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax SA (NASDAQ: ABVX), the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca. As of mid‑afternoon U.S. trading on Thursday, November 20, 2025, ABVX stock is trading around $121.94, up roughly 8% from Wednesday’s close of $112.95. Intraday, shares have ranged between about $113.63 and $126.42, on heavy volume of roughly 3.7 million American Depositary Shares (ADSs). Stock Invest That move adds to what has already been one of the biggest biotech runs of 2025. Abivax is up more than
20 November 2025
··

Stock Market Today

Real estate stocks rise as rate-cut bets return; XLRE ends at $41.99 ahead of payrolls and CPI

Real estate stocks rise as rate-cut bets return; XLRE ends at $41.99 ahead of payrolls and CPI

7 February 2026
U.S. real estate stocks rose Friday, with XLRE up 1.8% to $41.99 and VNQ and IYR each gaining 1.6%. The Dow closed above 50,000 for the first time as the 10-year Treasury yield ended at 4.206%. Bank of America downgraded Public Storage and Extra Space Storage, citing weak housing turnover and high borrowing costs. The delayed January jobs report is set for Feb. 11, with CPI due Feb. 13.
Go toTop